FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208122585> ?p ?o ?g. }

• W3208122585 endingPage "4384" @default.
• W3208122585 startingPage "4371" @default.
• W3208122585 abstract "Niraparib (Zejula), a selective oral PARP1/2 inhibitor registered for ovarian, fallopian tube, and primary peritoneal cancer treatment, is under investigation for other malignancies, including brain tumors. We explored the impact of the ABCB1 and ABCG2 multidrug efflux transporters, the OATP1A/1B uptake transporters, and the CYP3A drug-metabolizing complex on oral niraparib pharmacokinetics, using wild-type and genetically modified mouse and cell line models. In vitro, human ABCB1 and mouse Abcg2 transported niraparib moderately. Compared to wild-type mice, niraparib brain-to-plasma ratios were 6- to 7-fold increased in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- but not in single Abcg2-/- mice, while niraparib plasma exposure at later time points was ∼2-fold increased. Niraparib recovery in the small intestinal content was markedly reduced in the Abcb1a/1b-deficient strains. Pretreatment of wild-type mice with oral elacridar, an ABCB1/ABCG2 inhibitor, increased niraparib brain concentration and reduced small intestinal content recovery to levels observed in Abcb1a/1b;Abcg2-/- mice. Oatp1a/1b deletion did not significantly affect niraparib oral bioavailability or liver distribution but decreased metabolite M1 liver uptake. No significant effects of mouse Cyp3a ablation were observed, but overexpression of transgenic human CYP3A4 unexpectedly increased niraparib plasma exposure. Thus, Abcb1 deficiency markedly increased niraparib brain distribution and reduced its small intestinal content recovery, presumably through reduced biliary excretion and/or decreased direct intestinal excretion. Elacridar pretreatment inhibited both processes completely. Clinically, the negligible role of OATP1 and CYP3A could be advantageous for niraparib, diminishing drug-drug interaction or interindividual variation risks involving these proteins. These findings may support the further clinical development and application of niraparib." @default.
• W3208122585 created "2021-11-08" @default.
• W3208122585 creator A5020507978 @default.
• W3208122585 creator A5031730079 @default.
• W3208122585 creator A5041259777 @default.
• W3208122585 creator A5045217576 @default.
• W3208122585 creator A5062227574 @default.
• W3208122585 creator A5065973410 @default.
• W3208122585 creator A5074012409 @default.
• W3208122585 creator A5078774059 @default.
• W3208122585 creator A5089947472 @default.
• W3208122585 date "2021-11-03" @default.
• W3208122585 modified "2023-10-03" @default.
• W3208122585 title "P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib" @default.
• W3208122585 cites W1783939843 @default.
• W3208122585 cites W1966720603 @default.
• W3208122585 cites W1973508181 @default.
• W3208122585 cites W1987674565 @default.
• W3208122585 cites W1989818377 @default.
• W3208122585 cites W1989859921 @default.
• W3208122585 cites W1996963479 @default.
• W3208122585 cites W2005328285 @default.
• W3208122585 cites W2012431429 @default.
• W3208122585 cites W2021759214 @default.
• W3208122585 cites W2021775978 @default.
• W3208122585 cites W2033581016 @default.
• W3208122585 cites W2040628852 @default.
• W3208122585 cites W2045134358 @default.
• W3208122585 cites W2046826638 @default.
• W3208122585 cites W2047384307 @default.
• W3208122585 cites W2056772956 @default.
• W3208122585 cites W2062693496 @default.
• W3208122585 cites W2063873761 @default.
• W3208122585 cites W2063909696 @default.
• W3208122585 cites W2064437405 @default.
• W3208122585 cites W2079197876 @default.
• W3208122585 cites W2102967423 @default.
• W3208122585 cites W2111940011 @default.
• W3208122585 cites W2118207487 @default.
• W3208122585 cites W2120624849 @default.
• W3208122585 cites W2127059331 @default.
• W3208122585 cites W2135677264 @default.
• W3208122585 cites W2136487679 @default.
• W3208122585 cites W2148917087 @default.
• W3208122585 cites W2150549589 @default.
• W3208122585 cites W2160399783 @default.
• W3208122585 cites W2166153381 @default.
• W3208122585 cites W2514437732 @default.
• W3208122585 cites W2556646476 @default.
• W3208122585 cites W2595030994 @default.
• W3208122585 cites W2597062310 @default.
• W3208122585 cites W2604547648 @default.
• W3208122585 cites W2609619526 @default.
• W3208122585 cites W2698044357 @default.
• W3208122585 cites W2767170869 @default.
• W3208122585 cites W2770932522 @default.
• W3208122585 cites W2903876972 @default.
• W3208122585 cites W2911921008 @default.
• W3208122585 cites W2935541805 @default.
• W3208122585 cites W2954749227 @default.
• W3208122585 cites W2961419916 @default.
• W3208122585 cites W2971134471 @default.
• W3208122585 cites W2975141952 @default.
• W3208122585 cites W2979984433 @default.
• W3208122585 cites W2981132553 @default.
• W3208122585 cites W2999685584 @default.
• W3208122585 cites W3112616212 @default.
• W3208122585 cites W3124597687 @default.
• W3208122585 cites W3125948939 @default.
• W3208122585 cites W3126709178 @default.
• W3208122585 doi "https://doi.org/10.1021/acs.molpharmaceut.1c00553" @default.
• W3208122585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34730366" @default.
• W3208122585 hasPublicationYear "2021" @default.
• W3208122585 type Work @default.
• W3208122585 sameAs 3208122585 @default.
• W3208122585 citedByCount "3" @default.
• W3208122585 countsByYear W32081225852022 @default.
• W3208122585 countsByYear W32081225852023 @default.
• W3208122585 crossrefType "journal-article" @default.
• W3208122585 hasAuthorship W3208122585A5020507978 @default.
• W3208122585 hasAuthorship W3208122585A5031730079 @default.
• W3208122585 hasAuthorship W3208122585A5041259777 @default.
• W3208122585 hasAuthorship W3208122585A5045217576 @default.
• W3208122585 hasAuthorship W3208122585A5062227574 @default.
• W3208122585 hasAuthorship W3208122585A5065973410 @default.
• W3208122585 hasAuthorship W3208122585A5074012409 @default.
• W3208122585 hasAuthorship W3208122585A5078774059 @default.
• W3208122585 hasAuthorship W3208122585A5089947472 @default.
• W3208122585 hasConcept C104317684 @default.
• W3208122585 hasConcept C112705442 @default.
• W3208122585 hasConcept C11824378 @default.
• W3208122585 hasConcept C126322002 @default.
• W3208122585 hasConcept C133936738 @default.
• W3208122585 hasConcept C134018914 @default.
• W3208122585 hasConcept C149011108 @default.
• W3208122585 hasConcept C185592680 @default.
• W3208122585 hasConcept C2778707650 @default.
• W3208122585 hasConcept C44312359 @default.

• next